A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT03128164
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphomas
Interventions
DRUG:
HMPL-689
Sponsor
Hutchison Medipharma Limited